Interaction between susceptibility and environment: Examples from the digestive tract

Digestive Diseases

Volumn 29, Issue 2, 2011, Pages 136-143

  Rogler, Gerhard ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Commensal bacteria; Crohn's disease; Environment; Gut flora; Inflammatory bowel disease; Pattern recognition receptors; Susceptibility genes

Indexed keywords

AUTOPHAGY PROTEIN 16; BETA DEFENSIN 2; BETA DEFENSIN 5; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CHEMOKINE; CYTOKINE; FOOD ADDITIVE; MUTANT PROTEIN; NICOTINE; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PATTERN RECOGNITION RECEPTOR; PEPTIDES AND PROTEINS; REGULATOR PROTEIN; UNCLASSIFIED DRUG;

ADENOMATOUS POLYP; ALLELE; BACTERIAL PERITONITIS; CELIAC DISEASE; CHOLELITHIASIS; CIGARETTE SMOKING; CLINICAL FEATURE; COLORECTAL CANCER; CONFERENCE PAPER; CROHN DISEASE; CYSTIC FIBROSIS; DIET; DISEASE ASSOCIATION; DISEASE COURSE; DIZYGOTIC TWINS; DRUG USE; ENTERITIS; ENVIRONMENT; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; EPIGENETICS; FAST FOOD; FATTY LIVER; FOOD COMPOSITION; FOOD PROCESSING; FOOD STORAGE; GENETIC ASSOCIATION; GENETIC CODE; GENETIC DIFFERENCE; GENETIC RISK; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GERMFREE ANIMAL; HEPATITIS C; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; IMMUNITY; INTESTINE FLORA; LIFESTYLE; LIFESTYLE MODIFICATION; LYSIS; MONOZYGOTIC TWINS; NONHUMAN; PANCREATITIS; PATHOPHYSIOLOGY; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RELAPSE; RISK FACTOR; RISK REDUCTION; SEPSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SOCIAL PSYCHOLOGY; STRESS; TWIN CONCORDANCE; ULCERATIVE COLITIS; VIRUS INFECTION;

DIET; ENVIRONMENT; FOOD ADDITIVES; GASTROINTESTINAL TRACT; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATORY BOWEL DISEASES;

EID: 79960117507     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000323876     Document Type: Conference Paper

References (92)

1. Plomin R, Haworth CM, Davis OS: Common disorders are quantitative traits. Nat Rev Genet 2009; 10: 872-878.
2. Hampe J, Cuthbert A, Croucher PJ, Mirza MM, Mascheretti S, Fisher S, Frenzel H, King K, Hasselmeyer A, MacPherson AJ, Bridger S, van Deventer S, Forbes A, Nikolaus S, Lennard-Jones JE, Foelsch UR, Krawczak M, Lewis C, Schreiber S, Mathew CG: Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet 2001; 357: 1925-1928. (Pubitemid 32568333)
3. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, Almer S, Tysk C, O'Morain CA, Gassull M, Binder V, Finkel Y, Cortot A, Modigliani R, Laurent-Puig P, Gower-Rousseau C, Macry J, Colombel JF, Sahbatou M, Thomas G: Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411: 599-603. (Pubitemid 32531408)
4. Cho JH: Update on the genetics of inflammatory bowel disease. Curr Gastroenterol Rep 2001; 3: 458-463.
5. Borzutzky A, Fried A, Chou J, Bonilla FA, Kim S, Dedeoglu F: NOD2-associated diseases: bridging innate immunity and autoinflammation. Clin Immunol 2010; 134: 251-261.
6. Van Limbergen J, Wilson DC, Satsangi J: The genetics of Crohn's disease. Annu Rev Genomics Hum Genet 2009; 10: 89-116.
7. Fiocchi C: Susceptibility genes and overall pathogenesis of inflammatory bowel disease: where do we stand? Dig Dis 2009; 27: 226-235.
8. Melum E, Franke A, Karlsen TH: Genomewide association studies - a summary for the clinical gastroenterologist. World J Gastroenterol 2009; 15: 5377-5396.
9. Ruemmele FM: Pediatric inflammatory bowel diseases: coming of age. Curr Opin Gastroenterol 2010; 26: 332-336.
10. Amre DK, Mack DR, Morgan K, Israel D, Deslandres C, Seidman EG, Lambrette P, Costea I, Krupoves A, Fegury H, Dong J, Xhu Z, Grimard G, Levy E: Association between genome-wide association studies reported SNPs and pediatric-onset Crohn's disease in Canadian children. Hum Genet 2010; 128: 131-135.
11. Sanchez R, Levy E, Costea F, Sinnett D: IL-10 and TNF- κ promoter haplotypes are associated with childhood Crohn's disease location. World J Gastroenterol 2009; 15: 3776-3782.
12. Imielinski M, Baldassano RN, Griffiths A, Russell RK, Annese V, Dubinsky M, Kugathasan S, Bradfield JP, Walters TD, Sleiman P, Kim CE, Muise A, Wang K, Glessner JT, Saeed S, Zhang H, Frackelton EC, Hou C, Flory JH, Otieno G, Chiavacci RM, Grundmeier R, Castro M, Latiano A, Dallapiccola B, Stempak J, Abrams DJ, Taylor K, McGovern D, Silber G, Wrobel I, Quiros A, Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, Brant SR, Silverberg MS, Taylor KD, Barmuda MM, Bitton A, Dassopoulos T, Datta LW, Green T, Griffiths AM, Kistner EO, Murtha MT, Regueiro MD, Rotter JI, Schumm LP, Steinhart AH, Targan SR, Xavier RJ, Libioulle C, Sandor C, Lathrop M, Belaiche J, Dewit O, Gut I, Heath S, Laukens D, Mni M, Rutgeerts P, Van Gossum A, Zelenika D, Franchimont D, Hugot JP, de Vos M, Vermeire S, Louis E, Cardon LR, Anderson CA, Drummond H, Nimmo E, Ahmad T, Prescott NJ, Onnie CM, Fisher SA, Marchini J, Ghori J, Bumpstead S, Gwillam R, Tremelling M, Delukas P, Mansfield J, Jewell D, Satsangi J, Mathew CG, Parkes M, Georges M, Daly MJ, Heyman MB, Ferry GD, Kirschner B, Lee J, Essers J, Grand R, Stephens M, Levine A, Piccoli D, Van Limbergen J, Cucchiara S, Monos DS, Guthery SL, Denson L, Wilson DC, Grant SF, Daly M, Hakonarson H: Common variants at five new loci associated with early-onset inflammatory bowel disease. Nat Genet 2009; 41: 1335-1340.
13. Cooney R, Jewell D: The genetic basis of inflammatory bowel disease. Dig Dis 2009; 27: 428-442.
14. Lees CW, Satsangi J: Genetics of inflammatory bowel disease: Implications for disease pathogenesis and natural history. Expert Rev Gastroenterol Hepatol 2009; 3: 513-534.
15. Rath HC, Schultz M, Freitag R, Dieleman LA, Li F, Linde HJ, Scholmerich J, Sartor RB: Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice. Infect Immun 2001; 69: 2277-2285. (Pubitemid 32241818)
16. Rath HC, Wilson KH, Sartor RB: Differential induction of colitis and gastritis in HLAB27 transgenic rats selectively colonized with Bacteroides vulgatus or Escherichia coli. Infect Immun 1999; 67: 2969-2974. (Pubitemid 29244716)
17. Rath HC, Ikeda JS, Linde HJ, Scholmerich J, Wilson KH, Sartor RB: Varying cecal bacterial loads influences colitis and gastritis in HLA-B27 transgenic rats. Gastroenterology 1999; 116: 310-319. (Pubitemid 29055353)
18. Rath HC, Herfarth HH, Ikeda JS, Grenther WB, Hamm TE Jr, Balish E, Taurog JD, Hammer RE, Wilson KH, Sartor RB: Normal luminal bacteria, especially bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human κ 2 -microglobulin transgenic rats. J Clin Invest 1996; 98: 945-953. (Pubitemid 26293312)
19. Veltkamp C, Tonkonogy SL, De Jong YP, Albright C, Grenther WB, Balish E, Terhorst C, Sartor RB: Continuous stimulation by normal luminal bacteria is essential for the development and perpetuation of colitis in Tg( κ 26) mice. Gastroenterology 2001; 120: 900-913. (Pubitemid 32193187)
20. Moran JP, Walter J, Tannock GW, Tonkonogy SL, Sartor RB: Bifidobacterium animalis causes extensive duodenitis and mild colonic inflammation in monoassociated interleukin-10-deficient mice. Inflamm Bowel Dis 2009; 15: 1022-1031.
21. Sartor RB: Targeting enteric bacteria in treatment of inflammatory bowel diseases: why, how, and when. Curr Opin Gastroenterol 2003; 19: 358-365. (Pubitemid 36819789)
22. Schultz M, Tonkonogy SL, Sellon RK, Veltkamp C, Godfrey VL, Kwon J, Grenther WB, Balish E, Horak I, Sartor RB: IL-2-deficient mice raised under germ-free conditions develop delayed mild focal intestinal inflammation. Am J Physiol 1999; 276:G1461-G1472. (Pubitemid 29323453)
23. Duchmann R, Schmitt E, Knolle P, Meyer zum Buschenfelde KH, Neurath M: Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12. Eur J Immunol 1996; 26: 934-938.
24. Duchmann R, Kaiser I, Hermann E, Mayet W, Ewe K, Meyer zum Buschenfelde KH: Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease. Clin Exp Immunol 1995; 102: 448-455. (Pubitemid 26013210)
25. Swidsinski A, Loening-Baucke V, Bengmark S, Scholze J, Doerffel Y: Bacterial biofilm suppression with antibiotics for ulcerative and indeterminate colitis: consequences of aggressive treatment. Arch Med Res 2008; 39: 198-204.
26. Swidsinski A, Loening-Baucke V, Theissig F, Engelhardt H, Bengmark S, Koch S, Lochs H, Dorffel Y: Comparative study of the intestinal mucus barrier in normal and inflamed colon. Gut 2007; 56: 343-350. (Pubitemid 46579762)
27. Swidsinski A, Sydora BC, Doerffel Y, Loening-Baucke V, Vaneechoutte M, Lupicki M, Scholze J, Lochs H, Dieleman LA: Viscosity gradient within the mucus layer determines the mucosal barrier function and the spatial organization of the intestinal microbiota. Inflamm Bowel Dis 2007; 13: 963-970. (Pubitemid 47309967)
28. Canny G, Cario E, Lennartsson A, Gullberg U, Brennan C, Levy O, Colgan SP: Functional and biochemical characterization of epithelial bactericidal/permeability-increasing protein. Am J Physiol Gastrointest Liver Physiol 2006; 290:G557-G567.
29. Canny G, Swidsinski A, McCormick BA: Interactions of intestinal epithelial cells with bacteria and immune cells: methods to characterize microflora and functional consequences. Methods Mol Biol 2006; 341: 17-35.
30. Swidsinski A, Loening-Baucke V, Lochs H, Hale LP: Spatial organization of bacterial flora in normal and inflamed intestine: a fluorescence in situ hybridization study in mice. World J Gastroenterol 2005; 11: 1131-1140. (Pubitemid 40352998)
31. Swidsinski A, Weber J, Loening-Baucke V, Hale LP, Lochs H: Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease. J Clin Microbiol 2005; 43: 3380-3389. (Pubitemid 40981351)
32. Sydora BC, Martin SM, Lupicki M, Dieleman LA, Doyle J, Walker JW, Fedorak RN: Bacterial antigens alone can influence intestinal barrier integrity, but live bacteria are required for initiation of intestinal inflammation and injury. Inflamm Bowel Dis 2006; 12: 429-436.
33. Perminow G, Beisner J, Koslowski M, Lyckander LG, Stange E, Vatn MH, Wehkamp J: Defective paneth cell-mediated host defense in pediatric ileal Crohn's disease. Am J Gastroenterol 2010; 105: 452-459.
34. Koslowski MJ, Beisner J, Stange EF, Wehkamp J: Innate antimicrobial host defense in small intestinal Crohn's disease. Int J Med Microbiol 2010; 300: 34-40.
35. Wehkamp J, Stange EF, Fellermann K: Defensin immunology in inflammatory bowel disease. Gastroenterol Clin Biol 2009; 33 (suppl 3):S137-S144.
36. Bevins CL, Stange EF, Wehkamp J: Decreased paneth cell defensin expression in ileal Crohn's disease is independent of inflammation, but linked to the NOD2 1007fs genotype. Gut 2009; 58: 882-884.
37. Wehkamp J, Stange EF: Is there a role for defensins in IBD? Inflamm Bowel Dis 2008; 14(suppl 2):S85-S87.
38. Gersemann M, Wehkamp J, Fellermann K, Stange EF: Crohn's disease - defect in innate defence. World J Gastroenterol 2008; 14: 5499-5503.
39. Nuding S, Fellermann K, Wehkamp J, Stange EF: Reduced mucosal antimicrobial activity in Crohn's disease of the colon. Gut 2007; 56: 1240-1247. (Pubitemid 47300425)
40. Wehkamp J, Harder J, Weichenthal M, Schwab M, Schaffeler E, Schlee M, Herrlinger KR, Stallmach A, Noack F, Fritz P, Schroder JM, Bevins CL, Fellermann K, Stange EF: NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal κ -defensin expression. Gut 2004; 53: 1658-1664. (Pubitemid 39434112)
41. Wehkamp J, Koslowski M, Wang G, Stange EF: Barrier dysfunction due to distinct defensin deficiencies in small intestinal and colonic Crohn's disease. Mucosal Immunol 2008; 1(suppl 1):S67-S74.
42. Wehkamp J, Salzman NH, Porter E, Nuding S, Weichenthal M, Petras RE, Shen B, Schaeffeler E, Schwab M, Linzmeier R, Feathers RW, Chu H, Lima H Jr, Fellermann K, Ganz T, Stange EF, Bevins CL: Reduced paneth cell κ -defensins in ileal Crohn's disease. Proc Natl Acad Sci USA 2005; 102: 18129-18134. (Pubitemid 41798513)
43. Fellermann K, Stange DE, Schaeffeler E, Schmalzl H, Wehkamp J, Bevins CL, Reinisch W, Teml A, Schwab M, Lichter P, Radlwimmer B, Stange EF: A chromosome 8 gene-cluster polymorphism with low human κ -defensin 2 gene copy number predisposes to Crohn disease of the colon. Am J Hum Genet 2006; 79: 439-448. (Pubitemid 44384253)
44. Kim YS, Min KS, Lee SI, Shin SJ, Shin KS, Kim EC: Effect of proinflammatory cytokines on the expression and regulation of human κ -defensin 2 in human dental pulp cells. J Endod 2010; 36: 64-69.
45. Barreau F, Madre C, Meinzer U, Berrebi D, Dussaillant M, Merlin F, Eckmann L, Karin M, Sterkers G, Bonacorsi S, Lesuffleur T, Hugot JP: NOD2 regulates the host response towards microflora by modulating t cell function and epithelial permeability in mouse Peyer's patches. Gut 2010; 59: 207-217.
46. Gariboldi S, Palazzo M, Zanobbio L, Selleri S, Sommariva M, Sfondrini L, Cavicchini S, Balsari A, Rumio C: Low molecular weight hyaluronic acid increases the self-defense of skin epithelium by induction of κ -defensin 2 via TLR2 and TLR4. J Immunol 2008; 181: 2103-2110.
47. Cosnes J: Tobacco and IBD: relevance in the understanding of disease mechanisms and clinical practice. Best Pract Res Clin Gastroenterol 2004; 18: 481-496. (Pubitemid 38667461)
48. Cosnes J, Nion-Larmurier I, Afchain P, Beaugerie L, Gendre JP: Gender differences in the response of colitis to smoking. Clin Gastroenterol Hepatol 2004; 2: 41-48. (Pubitemid 38165398)
49. Cosnes J, Beaugerie L, Carbonnel F, Gendre JP: Smoking cessation and the course of Crohn's disease: an intervention study. Gastroenterology 2001; 120: 1093-1099. (Pubitemid 32246663)
50. Cosnes J, Carbonnel F, Beaugerie L, Le Quintrec Y, Gendre JP: Effects of cigarette smoking on the long-term course of Crohn's disease. Gastroenterology 1996; 110: 424-431. (Pubitemid 26043875)
51. Avidan B, Sakhnini E, Lahat A, Lang A, Koler M, Zmora O, Bar-Meir S, Chowers Y: Risk factors regarding the need for a second operation in patients with Crohn's disease. Digestion 2005; 72: 248-253. (Pubitemid 41820810)
52. Kane SV, Flicker M, Katz-Nelson F: Tobacco use is associated with accelerated clinical recurrence of Crohn's disease after surgically induced remission. J Clin Gastroenterol 2005; 39: 32-35. (Pubitemid 40041340)
53. Calkins BM: A meta-analysis of the role of smoking in inflammatory bowel disease. Dig Dis Sci 1989; 34: 1841-1854. (Pubitemid 20018648)
54. Mahid SS, Minor KS, Stevens PL, Galandiuk S: The role of smoking in Crohn's disease as defined by clinical variables. Dig Dis Sci 2007; 52: 2897-2903. (Pubitemid 47512518)
55. Cosnes J: Smoking, physical activity, nutrition and lifestyle: environmental factors and their impact on IBD. Dig Dis 2010; 28: 411-417.
56. Johnson GJ, Cosnes J, Mansfield JC: Smoking cessation as primary therapy to modify the course of Crohn's disease. Aliment Pharmacol Ther 2005; 21: 921-931. (Pubitemid 40529727)
57. Lakatos PL, Szamosi T, Lakatos L: Smoking in inflammatory bowel diseases: good, bad or ugly? World J Gastroenterol 2007; 13: 6134-6139.
58. Thia KT, Sandborn WJ, Harmsen WS, Zinsmeister AR, Loftus EV Jr: Risk factors associated with progression to intestinal complications of Crohn's disease in a populationbased cohort. Gastroenterology 2010; 139: 1147-1155.
59. Cunningham MF, Docherty NG, Coffey JC, Burke JP, O'Connell PR: Postsurgical recurrence of ileal Crohn's disease: an update on risk factors and intervention points to a central role for impaired host-microflora homeostasis. World J Surg 2010; 34: 1615-1626.
60. Dotan I: Disease behavior in adult patients: are there predictors for stricture or fistula formation? Dig Dis 2009; 27: 206-211.
61. Aldhous MC, Drummond HE, Anderson N, Smith LA, Arnott ID, Satsangi J: Does cigarette smoking influence the phenotype of Crohn's disease? Analysis using the Montreal classification. Am J Gastroenterol 2007; 102: 577-588. (Pubitemid 46328158)
62. Papi C, Festa V, Fagnani C, Stazi A, Antonelli G, Moretti A, Koch M, Capurso L: Evolution of clinical behaviour in Crohn's disease: predictive factors of penetrating complications. Dig Liver Dis 2005; 37: 247-253. (Pubitemid 41070522)
63. Louis E, Michel V, Hugot JP, Reenaers C, Fontaine F, Delforge M, El Yafi F, Colombel JF, Belaiche J: Early development of stricturing or penetrating pattern in Crohn's disease is influenced by disease location, number of flares, and smoking but not by NOD2/CARD15 genotype. Gut 2003; 52: 552-557. (Pubitemid 36363410)
64. Reese GE, Nanidis T, Borysiewicz C, Yamamoto T, Orchard T, Tekkis PP: The effect of smoking after surgery for Crohn's disease: a meta-analysis of observational studies. Int J Colorectal Dis 2008; 23: 1213-1221.
65. Yamamoto T: Factors affecting recurrence after surgery for Crohn's disease. World J Gastroenterol 2005; 11: 3971-3979. (Pubitemid 41235590)
66. Yamamoto T, Keighley MR: Smoking and disease recurrence after operation for Crohn's disease. Br J Surg 2000; 87: 398-404. (Pubitemid 30192945)
67. Yamamoto T, Keighley MR: The association of cigarette smoking with a high risk of recurrence after ileocolonic resection for ileocecal Crohn's disease. Surg Today 1999; 29: 579-580. (Pubitemid 29313975)
68. Van der Heide F, Dijkstra A, Weersma RK, Albersnagel FA, van der Logt EM, Faber KN, Sluiter WJ, Kleibeuker JH, Dijkstra G: Effects of active and passive smoking on disease course of Crohn's disease and ulcerative colitis. Inflamm Bowel Dis 2009; 15: 1199-1207.
69. Katschinski B, Logan RF, Edmond M, Langman MJ: Smoking and sugar intake are separate but interactive risk factors in Crohn's disease. Gut 1988; 29: 1202-1206.
70. Jarnerot G, Jarnmark I, Nilsson K: Consumption of refined sugar by patients with Crohn's disease, ulcerative colitis, or irritable bowel syndrome. Scand J Gastroenterol 1983; 18: 999-1002. (Pubitemid 14200826)
71. Silkoff K, Hallak A, Yegena L, Rozen P, Mayberry JF, Rhodes J, Newcombe RG: Consumption of refined carbohydrate by patients with Crohn's disease in Tel-Aviv-Yafo. Postgrad Med J 1980; 56: 842-846. (Pubitemid 11155121)
72. Thornton JR, Emmett PM, Heaton KW: Diet and Crohn's disease: characteristics of the pre-illness diet. Br Med J 1979; 2: 762-764. (Pubitemid 10231334)
73. Martini GA, Brandes JW: Increased consumption of refined carbohydrates in patients with Crohn's disease. Klin Wochenschr 1976; 54: 367-371.
74. Persson PG, Ahlbom A, Hellers G: Diet and inflammatory bowel disease: a case-control study. Epidemiology 1992; 3: 47-52.
75. Bartel G, Weiss I, Turetschek K, Schima W, Puspok A, Waldhoer T, Gasche C: Ingested matter affects intestinal lesions in Crohn's disease. Inflamm Bowel Dis 2008; 14: 374-382. (Pubitemid 351441327)
76. Gibson PR, Shepherd SJ: Personal view: food for thought - Western lifestyle and susceptibility to Crohn's disease. The FODMAP hypothesis. Aliment Pharmacol Ther 2005; 21: 1399-1409. (Pubitemid 40874156)
77. Ahuja V, Tandon RK: Inflammatory bowel disease in the Asia-Pacific area: a comparison with developed countries and regional differences. J Dig Dis 2010; 11: 134-147.
78. Yoshida Y, Murata Y: Inflammatory bowel disease in Japan: studies of epidemiology and etiopathogenesis. Med Clin North Am 1990; 74: 67-90.
79. Leong RW, Lau JY, Sung JJ: The epidemiology and phenotype of Crohn's disease in the Chinese population. Inflamm Bowel Dis 2004; 10: 646-651. (Pubitemid 39276475)
80. Zheng JJ, Zhu XS, Huangfu Z, Shi XH, Guo ZR: Prevalence and incidence rates of Crohn's disease in mainland china: a metaanalysis of 55 years of research. J Dig Dis 2010; 11: 161-166.
81. Wang YF, Ouyang Q, Hu RW: Progression of inflammatory bowel disease in China. J Dig Dis 2010; 11: 76-82.
82. Korzenik JR: Past and current theories of etiology of IBD: toothpaste, worms, and refrigerators. J Clin Gastroenterol 2005; 39:S59-65. (Pubitemid 40397017)
83. Carbonnel F, Jantchou P, Monnet E, Cosnes J: Environmental risk factors in Crohn's disease and ulcerative colitis: an update. Gastroenterol Clin Biol 2009; 33(suppl 3):S145-157.
84. Cosnes J, Carbonnel F, Carrat F, Beaugerie L, Gendre JP: Oral contraceptive use and the clinical course of Crohn's disease: a prospective cohort study. Gut 1999; 45: 218-222. (Pubitemid 29333770)
85. Danese S, Sans M, Fiocchi C: Inflammatory bowel disease: the role of environmental factors. Autoimmun Rev 2004; 3: 394-400. (Pubitemid 38993362)
86. Wakefield AJ, Sawyerr AM, Hudson M, Dhillon AP, Pounder RE: Smoking, the oral contraceptive pill, and Crohn's disease. Dig Dis Sci 1991; 36: 1147-1150.
87. Takeuchi K, Smale S, Premchand P, Maiden L, Sherwood R, Thjodleifsson B, Bjornsson E, Bjarnason I: Prevalence and mechanism of non-steroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2006; 4: 196-202. (Pubitemid 43199690)
88. Sandborn WJ, Stenson WF, Brynskov J, Lorenz RG, Steidle GM, Robbins JL, Kent JD, Bloom BJ: Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study. Clin Gastroenterol Hepatol 2006; 4: 203-211. (Pubitemid 43199691)
89. Cámara RJ, Lukas PS, Begré S, Pittet V, von Känel R, Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS) Group: Effects of social support on the clinical course of Crohn's disease. Inflamm Bowel Dis 2010, Epub ahead of print.
90. Levenstein S: Psychosocial factors in peptic ulcer and inflammatory bowel disease. J Consult Clin Psychol 2002; 70: 739-750. (Pubitemid 34640740)
91. Prescott NJ, Dominy KM, Kubo M, Lewis CM, Fisher SA, Redon R, Huang N, Stranger BE, Blaszczyk K, Hudspith B, Parkes G, Hosono N, Yamazaki K, Onnie CM, Forbes A, Dermitzakis ET, Nakamura Y, Mansfield JC, Sanderson J, Hurles ME, Roberts RG, Mathew CG: Independent and populationspecific association of risk variants at the IRGM locus with Crohn's disease. Hum Mol Genet 2010; 19: 1828-1839.
92. Cadwell K, Patel KK, Maloney NS, Liu TC, Ng AC, Storer CE, Head RD, Xavier R, Stappenbeck TS, Virgin HW: Virus-plus-susceptibility gene interaction determines Crohn's disease gene ATG16L1 phenotypes in intestine. Cell 2010; 141: 1135-1145.